Skip to main content

Dawn (Dan) Zhang is Co-Managing Shareholder of the Shanghai Office and Co-Chair of the firm's China Practice. Dawn has broad experience advising clients on China-related cross-border mergers and acquisitions, restructuring, joint ventures, funds, and general corporate matters. Before joining Greenberg Traurig, Dawn practiced in other international law firms for many years and served as the PRC legal counsel for a multinational corporation, where she handled a wide variety of corporate matters for public and emerging growth companies. Dawn passed the national PRC judicial qualification examination in 1998 and is admitted to practice in New York.


  • Mergers and acquisitions
  • Funds
  • Foreign direct investment
  • Corporate governance and compliance
  • Life sciences



  • Assisted PRA in forming a CRO joint venture with Wuxi PharmaTech to carry out Phase I-IV clinical trial services in China.
  • Assisted a global leader in business process and technology management in acquiring majority equity interest of a BPO service provider (under VIE structure) in Shanghai.
  • Assisted a consulting firm in selling their equity interest in a HK company and its Shanghai WFOE to a world leading consulting firm.
  • Acted as the primary lawyer in China to assist a leading OEM multinational corporation in acquiring a target company’s notebook PC OEM business for US$ 200 million.
  • Advised and assisted a leading U.S. automotive company in setting up in China an equity joint venture with a large PRC state-owned automotive company.
  • Represented the world’s largest contract manufacturer of wire formed medical devices and components in its strategic investment in a HK medical device company and its PRC subsidiaries.
  • Conducted in-depth due diligence and handled transactional documents for a research laboratory company with US$ 3 billion in annual sales for its US$ 30 million strategic investment in a PRC medical device group.
  • Represented a network infrastructure products and services provider in acquiring the equity interest of a PRC telecommunications equipment group for US$ 70 million.
  • Represented a leading NYSE-listed building products manufacturer in restructuring of its BVI and PRC subsidiaries, and in acquisition of a household appliance factory in Huizhou, China.
  • Acted as investor counsel in a US$20 million A round investment in a vaccine company in China.
  • Acted as investor counsel in a US$ 60 million A round investment in a Nanjing pharmaceutical company.
  • Acted as investor counsel in a US$ 10 million A round investment in an online underwear company in Guangzhou.
  • Acted as investor counsel in a RMB 20 million A round investment in a health care management company in Beijing.
  • Acted as company counsel of a media advertisement company in accepting investments from angel investors and VC investors.
  • Advised as investor counsel on A and B rounds investment in a mining company.
  • Acted as company counsel of a pharmaceutical company in Chengdu with a registered capital of US$ 50 million inn accepting investment from syndicate VC investors.
  • Acted as company counsel in a RMB 35 million VC financing in a railway systems R&D company.
  • Acted as company counsel of a Nantong company in a US$ 75 million Series A financing by syndicate investors.
  • Provided trainings on FCPA and anti-bribery laws; assisted in developing and implementing corporate compliance program (FCPA); Created code of conduct.
  • Franchise and licensing
    • Industries include: life sciences (drugs, vaccines, medical devices, CROs, APIs, clinics, bio-engineering, health care, etc.), automobile, retailer, internet and emerging technology, manufacturing, etc.


  • Listed, Asian Legal Business, "Top 15 Rising Lawyers," 2014


  • LL.M., University of Pennsylvania Law School
  • LL.B., Fudan University School of Law
  • New York
  • Passed national PRC judicial qualification examination in 1998
  • 中文普通话, 流利
  • 英文, 流利